Zepbound coupon and savings card: self-pay vials and other channels
Prices in US dollars at the verification date. Ranges are published list or program prices where a primary source exists; notes say when a figure is a typical market range instead.
| Channel | Price (USD) | Notes |
|---|---|---|
| Savings card for Zepbound with commercial insurance | From $25per month | The manufacturer savings card is what people search for as the "Zepbound coupon". When a commercial plan covers Zepbound, the savings card lets eligible patients pay as little as $25 for a one or three month supply of single-dose pens, subject to monthly and annual limits; government beneficiaries are excluded (checked 2026-09-22). Commercially insured patients with type 2 diabetes can use a separate savings card for Mounjaro. Plans that exclude weight management drugs may still cover Mounjaro for type 2 diabetes or Zepbound for obstructive sleep apnea; standard Medicare Part D coverage does not extend to drugs prescribed only for weight loss; the separate Medicare GLP-1 Bridge row covers that case. [1] [2] [11] [14] |
| Medicare GLP-1 Bridge | $50per month | Under the Medicare GLP-1 Bridge, a CMS demonstration running from July 1, 2026 to December 31, 2027, eligible adults with Medicare Part D pay a $50 copay for a one-month supply of the Zepbound KwikPen prescribed for weight management; single-dose Zepbound vials and pens are not covered (checked 2026-09-22). Eligibility is set by BMI and qualifying conditions, prior authorization is required, and people with type 2 diabetes, moderate to severe sleep apnea, or fatty liver disease are excluded because their Part D plan may cover a GLP-1 instead. The copay does not count toward the Part D deductible or out-of-pocket limit. [9] [10] |
| List price (Zepbound and Mounjaro) | $499 to $1,112per month | Manufacturer list price (wholesale acquisition cost) per one-month fill before insurance, as published on the manufacturer's pricing pages (list prices accessed by the manufacturer on January 1, 2026; pages checked 2026-09-22): Zepbound $499 to $1,086.37 per fill depending on the product, and Mounjaro $1,112.16 for a month of four pens. Retail pharmacies may add a margin. [1] [2] |
| Self-pay Zepbound vials and KwikPen | $299 to $699per month | Manufacturer direct-to-patient self-pay prices for a 28 day supply of Zepbound as four single-dose vials or one multi-dose KwikPen, checked 2026-09-22: $299 at 2.5 mg, 399 at 5 mg, 499 at 7.5 mg, and 699 at 10 mg, 12.5 mg, and 15 mg. A manufacturer purchase offer lowers the 7.5 mg to 15 mg KwikPen to $449 per month when each refill is completed within 45 days, through December 31, 2026. Mounjaro is also sold self-pay, starting at $499 per month at every dose. [1] [3] [4] |
| Telehealth program | $373 to $598per month | A licensed telehealth provider's published price, checked 2026-09-22: a program membership of $74 per month on an annual prepaid plan up to $149 on a month-to-month plan ($39 for the first month), plus the Zepbound KwikPen billed at the manufacturer self-pay price ($299 at 2.5 mg, 399 at 5 mg, 449 at 7.5 mg to 15 mg with the manufacturer refill offer). Membership plus medication comes to about $373 to $598 per month; the page lists the 7.5 mg to 15 mg price only with the manufacturer offer applied. [3] [8] |
| Compounded pharmacy (2024 survey) | $275 to $399per month | Historical price from a peer-reviewed study of websites selling compounded GLP-1 drugs, searched July to September 2024 during the shortage: 57 of 79 sites sold compounded tirzepatide, at a median first-month price of $330, interquartile range $275 to $399, including discounts. No current dated lawful price was found. Since the FDA 503A grace period ended on February 18, 2025 (503B on March 19, 2025), compounded tirzepatide is limited to documented patient specific needs, and on March 3, 2026 the FDA announced 30 warning letters to telehealth companies over false or misleading claims about compounded GLP-1 products. Adding a vitamin such as B12 or niacinamide does not by itself make a compounded GLP-1 different from the approved drug. Under FDA's April 1, 2026 policy update, such a combination may be treated as essentially a copy when the strengths are within 10% of approved products and the route is the same, unless a prescriber documents a real difference for the individual patient. A September 2026 FDA warning letter applied this to semaglutide and tirzepatide vitamin combinations, said high production volume suggested the claimed differences were a pretext, and questioned significant-difference statements picked from preset menus on prescribing platforms. [5] [6] [7] [12] [13] |
Zepbound list price vs the cheapest lawful option
List prices are manufacturer wholesale acquisition costs for a one-month fill: Zepbound $499 to $1,086.37 per fill depending on the product and Mounjaro $1,112.16 at the verification date. The self-pay vial and KwikPen program is priced by dose and sits far below list because it bypasses pharmacy benefit managers.
Which insurance covers Zepbound?
Which insurance covers Zepbound depends on the indication. Mounjaro for type 2 diabetes is widely covered; Zepbound for chronic weight management is excluded by many employer plans and by Medicare Part D when prescribed for weight loss alone. The December 2024 obstructive sleep apnea indication gives some patients a covered pathway to Zepbound. From July 1, 2026 to December 31, 2027, the Medicare GLP-1 Bridge demonstration covers the Zepbound KwikPen (not vials or single-dose pens) for weight management at a $50 monthly copay for eligible Part D enrollees. Manufacturer savings cards apply to commercial insurance only. From October 1, 2026, one of the largest pharmacy benefit managers added Zepbound back to its most common commercial template formularies as an additional preferred option, so members of employer plans that use those formularies and choose to cover weight management drugs may have Zepbound covered; plan sponsors can still customize or exclude coverage.
What changes the price?
- Without insurance, the lowest published lawful price is the manufacturer self-pay vial or KwikPen at $299 per month for the 2.5 mg starting dose (checked 2026-09-22); compounded copies are no longer a routine lawful option
- Whether the prescription is for a covered indication (type 2 diabetes, obstructive sleep apnea) or for weight loss alone
- Single-dose pen at list price versus manufacturer self-pay vial or KwikPen
- Dose strength: self-pay pricing rises from $299 at the 2.5 mg starting dose to $699 at 10 mg and above
- Refilling on time, which keeps the manufacturer $449 refill offer for the 7.5 mg and higher KwikPen
- Telehealth membership fees charged on top of the drug
- Availability of a manufacturer savings card with commercial insurance
Frequently asked questions
How much does tirzepatide cost without insurance?
About $275 to $1,112 per month at the verification date, depending on the channel: list price (Zepbound and Mounjaro), self-pay Zepbound vials and KwikPen, compounded pharmacy (2024 survey), telehealth program. See the table above for what each figure includes. [1] [2] [3] [4] [5] [6] [7] [8] [12] [13]
Does insurance cover tirzepatide?
Which insurance covers Zepbound depends on the indication. Mounjaro for type 2 diabetes is widely covered; Zepbound for chronic weight management is excluded by many employer plans and by Medicare Part D when prescribed for weight loss alone. The December 2024 obstructive sleep apnea indication gives some patients a covered pathway to Zepbound. From July 1, 2026 to December 31, 2027, the Medicare GLP-1 Bridge demonstration covers the Zepbound KwikPen (not vials or single-dose pens) for weight management at a $50 monthly copay for eligible Part D enrollees. Manufacturer savings cards apply to commercial insurance only. From October 1, 2026, one of the largest pharmacy benefit managers added Zepbound back to its most common commercial template formularies as an additional preferred option, so members of employer plans that use those formularies and choose to cover weight management drugs may have Zepbound covered; plan sponsors can still customize or exclude coverage. [1] [2] [9] [10] [11] [14]
What is the list price of tirzepatide?
List prices are manufacturer wholesale acquisition costs for a one-month fill: Zepbound $499 to $1,086.37 per fill depending on the product and Mounjaro $1,112.16 at the verification date. The self-pay vial and KwikPen program is priced by dose and sits far below list because it bypasses pharmacy benefit managers. [1] [2] [3] [4]
Related pages
- Tirzepatide: evidence, legality, and access
- Zepbound vs Mounjaro
- Semaglutide vs tirzepatide (Semaglutide cost)
- Tirzepatide vs cagrilintide
- Tirzepatide vs dulaglutide (Dulaglutide cost)
- Tirzepatide vs liraglutide (Liraglutide cost)
- Tirzepatide vs mazdutide
- Tirzepatide vs retatrutide (Retatrutide cost)
- Tirzepatide vs survodutide
- Obesity and chronic weight management: peptide evidence
- Type 2 diabetes: peptide evidence
- Sleep disorders: peptide evidence
- Fatty liver disease (MASLD and MASH): peptide evidence
- Obstructive sleep apnea: peptide evidence
- Fat loss and body composition: peptide evidence
- Where it is legal to get: peptide law by state
- Full cost index
From the blog
- Compounded tirzepatide in 2026: legality, cost, and safety
The tirzepatide shortage ended in December 2024 and routine compounded copies ended in 2025. What is still lawful, what it cost, FDA safety warnings, and how to check a pharmacy.
- Do GLP-1 patches work? What they contain and what the evidence says
No FDA-approved GLP-1 patch exists. Here is why GLP-1 drugs cannot pass through skin from a sticker, what patch ingredients have been tested by mouth, and how to read patch reviews.
- GLP-1 supplements vs GLP-1 drugs: what GLP-1 boosters actually do
Berberine, fiber, and probiotics sold as GLP-1 boosters are not GLP-1 drugs. Here is the human evidence for each ingredient, graded, and how it compares with semaglutide and tirzepatide.
- Microdosing GLP-1s and tirzepatide: what the evidence says
No trial has tested microdosing semaglutide or tirzepatide. What the labels say about dose steps and why they exist, FDA's dosing-error warnings, and what to ask a prescriber.
- Peptides for weight loss, ranked by human evidence
Tirzepatide, semaglutide, and liraglutide lead on human trials. Retatrutide is trial-only, and AOD-9604 and 5-amino-1MQ are animal-only. Ranking, legal status, and dated prices.
- Can you get a GLP-1 through telehealth in your state?
Yes in every state, but the rules for the visit, the prescriber's license, and the pharmacy differ. How state telehealth law shapes GLP-1 access, with ten state examples.
More on the blog
Sources
- [1]Manufacturer pricing information page for tirzepatide for weight management: list price, self-pay prices by dose, and commercial savings card, accessed 2026-09-222026
- [2]Manufacturer pricing information page for tirzepatide for type 2 diabetes: list price and savings card eligibility, accessed 2026-09-222026
- [3]Manufacturer savings and self-pay terms for tirzepatide for weight management, including the KwikPen refill offer, accessed 2026-09-222026
- [4]Manufacturer direct-to-patient pharmacy page with self-pay prices for tirzepatide for type 2 diabetes, accessed 2026-09-222026
- [5]Online advertising of compounded glucagon-like peptide-1 receptor agonists (JAMA Health Forum, 2025): cross-sectional study of 79 websites with first-month pricesPubMed 39820389, 2025
- [6]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
- [7]FDA: warning letters to 30 telehealth companies over marketing of compounded GLP-1 products (March 3, 2026)FDA, 2026
- [8]Licensed telehealth provider price page (weight management membership and GLP-1 self-pay prices), accessed 2026-09-222026
- [9]Medicare.gov: weight loss drugs, Medicare GLP-1 Bridge coverage, eligibility, and $50 copay, accessed 2026-09-222026
- [10]CMS: Medicare GLP-1 Bridge, a demonstration from July 1, 2026 to December 31, 2027, accessed 2026-09-222026